parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (1707 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 105	0.85
pathways Reactome	7 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 13049

CLASP2 in dopamine neurons, braak+0.19 (p 0.630) → +0.08 (p 0.842)receipt 13058
CLASP2 in oligodendrocytes, braak-0.06 (p 0.877) → +0.50 (p 0.172)receipt 13057

receipt 13058: CLASP2 in dopamine neurons, braak

power: full sample +0.09 (p 0.728, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.13 (p 0.615, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.34 (p 0.161, n 18). could be the mix.
skeptic: leave-one-out range -0.03 to +0.23, sign flips 2; without severely affected donors +0.09 (p 0.728, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CLASP2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 13057: CLASP2 in oligodendrocytes, braak

power: full sample +0.22 (p 0.379, n 18), 95% CI -0.27 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.19 (p 0.439, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.26 (p 0.294, n 18). could be the mix.
skeptic: leave-one-out range +0.12 to +0.35, sign flips 0; without severely affected donors +0.22 (p 0.379, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CLASP2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts